We are excited to be profiled by Stockhead in The Australian with the publication showcasing our promising Photosoft technology in fighting cancers. Click here to read more theaustralian.com.au/busines… #stockstofocus #ASX #Biotechnology #investing #Oncology #CancerResearch

Following our positive Phase 2 Prostate Cancer Trial results, many have asked how Photosoft works. This 1 minute animation explains the mechanism of action #CancerResearch #ASX #biotech #StocksInFocus #Stocks #stockinvesting #SmallCaps

Webinar where Invion's CEO, Thian Chew, spoke about the successful Ph 2 prostate cancer results, the Ph 1/2 skin cancer trial and what these mean for Invion in the near-term. youtube.com/watch?v=QttqRDHv… #investing #investments #cancerresearch #ASX #stockstowatch #smallcaps #biotech

Results from Ph 2 prostate cancer trial using INV043 showed it to be safe & well tolerated by patients, 40% showed a positive response using RECIST 1.1 (10% complete regression) & 44% negative on PSMA-PET. investors.inviongroup.com/an… #asx #smallcaps #CancerResearch #investing

Invion's (ASX: IVX) CEO Thian Chew speaks with 180 Markets about what makes Invion's next-gen PDT technology so unique as a potential cancer treatment @180Markets #markets #health #healthtech #cancer #asxnews #biotech youtube.com/watch?v=dn24VX8g…

.@InvionLimited & the Hudson Institute, have announced significant in vitro data for the new IVXP02 PhotosoftTM formulation, including a validated at 15x potency compared to other PDT treatments for ovarian cancer cells. See more here - youtu.be/dbvDMAr4DXQ #IVX #ASX #ausbio

Mitchell Glass, M.D. discusses Invion's two drug assets and three phase II clinical programs - asthma, CB and lupus youtube.com/watch?v=cWgu5MxC…